Esperion Therapeutics Inc. (NASDAQ:ESPR) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Monday.
According to Zacks, “Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan. “
Several other equities research analysts have also issued reports on the stock. Stifel Nicolaus restated a “buy” rating and issued a $30.00 target price (down previously from $64.00) on shares of Esperion Therapeutics in a report on Saturday. Chardan Capital restated a “neutral” rating and issued a $12.50 target price on shares of Esperion Therapeutics in a report on Saturday. Credit Suisse Group AG raised their target price on shares of Esperion Therapeutics from $10.00 to $14.00 and gave the stock an “underperform” rating in a report on Friday. Barclays PLC set a $13.00 target price on shares of Esperion Therapeutics and gave the stock a “hold” rating in a report on Wednesday, August 31st. Finally, Vetr lowered shares of Esperion Therapeutics from a “strong-buy” rating to a “buy” rating and set a $12.60 target price for the company. in a report on Tuesday, August 23rd. One analyst has rated the stock with a sell rating, six have given a hold rating and seven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $26.36.
Shares of Esperion Therapeutics (NASDAQ:ESPR) traded up 1.58% during midday trading on Monday, reaching $12.24. 428,358 shares of the company’s stock were exchanged. The company’s market cap is $276.01 million. The stock’s 50 day moving average price is $12.34 and its 200 day moving average price is $13.96. Esperion Therapeutics has a 12-month low of $9.58 and a 12-month high of $30.41.
Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.16. During the same quarter in the previous year, the firm earned ($0.55) earnings per share. Equities analysts anticipate that Esperion Therapeutics will post ($3.37) earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently bought and sold shares of ESPR. Quantitative Investment Management LLC acquired a new position in Esperion Therapeutics during the second quarter worth approximately $111,000. Advisor Group Inc. purchased a new position in shares of Esperion Therapeutics during the second quarter worth about $140,000. Stifel Financial Corp increased its position in shares of Esperion Therapeutics by 10.6% in the second quarter. Stifel Financial Corp now owns 15,017 shares of the biopharmaceutical company’s stock worth $148,000 after buying an additional 1,438 shares during the last quarter. Rhumbline Advisers increased its position in shares of Esperion Therapeutics by 27.0% in the second quarter. Rhumbline Advisers now owns 17,186 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 3,657 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new position in shares of Esperion Therapeutics during the first quarter worth about $313,000. 65.23% of the stock is currently owned by institutional investors and hedge funds.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.